2022
Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer
Salahuddin S, Cohen O, Wu M, Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Prasad M, Schalper K, Mehra S, Yarbrough W, Emu B. Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer. Clinical Infectious Diseases 2022, 76: 1449-1458. PMID: 36520995, PMCID: PMC10319962, DOI: 10.1093/cid/ciac924.Peer-Reviewed Original ResearchConceptsOverall survivalIndependent predictorsHNSCC patientsWorse prognosisOropharyngeal tumorsCox proportional hazards regression modelMultivariate analysisHPV-positive oropharyngeal tumorsNeck squamous cell cancerProportional hazards regression modelsLower median overall survivalAcademic hospital centerNon-HIV populationMedian overall survivalPredictors of survivalSquamous cell cancerHuman immunodeficiency virusPoor clinical outcomeExpression of CD4Poor overall survivalHazards regression modelsRace/ethnicityCD8 infiltrationHazard ratioClinicopathologic characteristicsDensity patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057.
Corredor G, Ding R, Prasanna P, Barrera C, Toro P, Viswanathan V, Zens P, Berezowska S, Baxi V, Balli D, Belete M, Velcheti V, Schalper K, Madabhushi A. Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057. Journal Of Clinical Oncology 2022, 40: 2662-2662. DOI: 10.1200/jco.2022.40.16_suppl.2662.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesImmune checkpoint inhibitorsOverall survivalLung adenocarcinomaCheckMate 057Objective responseRisk scoreAnalysis of TILAdvanced-stage lung adenocarcinomaPlatinum-based chemotherapyRisk of progressionCox regression modelDeath risk scoreStage lung adenocarcinomaLung cancer subjectsRECIST v1.1Checkpoint inhibitorsHazard ratioTIL densityPD-L1Better prognosisTumor responseClinical trialsCancer subjectsNivolumab
2019
Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.
Lu B, Gupta R, Stewart T, Kluger H, Jilaveanu L, Schalper K, Goldberg S. Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases. Journal Of Clinical Oncology 2019, 37: 2066-2066. DOI: 10.1200/jco.2019.37.15_suppl.2066.Peer-Reviewed Original ResearchPrimary lung tumorsMajor T cell subsetsMultiplexed quantitative immunofluorescenceT cell subsetsExtracranial metastasesT cellsLung tumorsBrain metastasesQuantitative immunofluorescenceAdaptive anti-tumor responsesLow T cell infiltrationMajor clinicopathologic variablesYale Cancer CenterAdaptive immune cellsRegulatory T cellsT cell infiltrationAnti-tumor responseLonger overall survivalOptimal treatment strategyLung cancer patientsKi-67 levelsLung cancer histologyLymphocyte subsetsOverall survivalPrimary malignancy
2017
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. Journal For ImmunoTherapy Of Cancer 2017, 5: 81. PMID: 29037255, PMCID: PMC5644103, DOI: 10.1186/s40425-017-0285-7.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerIDO1 expressionBreast cancerIndependent negative prognostic markerB cell infiltrationImmune suppressive pathwaysAdvanced solid tumorsTumor-infiltrating lymphocytesT cell responsesClinico-pathological featuresClinico-pathological characteristicsProportional hazards modelNegative prognostic markerDegradation of tryptophanMann-Whitney testFoxp3 levelsIDO1 blockadeIDO1 levelsEffector CD4Durable responsesOverall survivalImmune toleranceMultivariable analysisPrognostic markerB7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes
Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research 2017, 23: 5202-5209. PMID: 28539467, PMCID: PMC5581684, DOI: 10.1158/1078-0432.ccr-16-3107.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedB7 AntigensB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell Line, TumorDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisV-Set Domain-Containing T-Cell Activation Inhibitor 1ConceptsNon-small cell lung cancerTumor-infiltrating lymphocytesB7-H3 proteinB7-H4PD-L1B7-H3Majority of NSCLCQuantitative immunofluorescenceImmune checkpoints PD-1Major clinicopathologic variablesLevels of CD3Negative prognostic impactCell lung cancerPoor overall survivalSuccessful therapeutic targetsB7 family membersClin Cancer ResB7-H1NSCLC cohortOverall survivalPrognostic impactSmoking historyClinicopathologic characteristicsPD-1Clinical stage
2014
Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.
Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointestinal Cancer Research : GCR 2014, 7: 42-8. PMID: 24799970, PMCID: PMC4007675.Peer-Reviewed Original ResearchHER2/neu overexpressionHER2/neu geneGallbladder cancerHER2/neuNeu overexpressionHER2/neu expressionNeu geneHer2/neu pathwaySubgroup of patientsWorse overall survivalAdvanced gallbladder cancerSingle large studyAnti-ErbB2 antibodyNew therapeutic possibilitiesGallbladder cancer casesASCO criteriaOverall survivalAdvanced cancerControl subjectsNeu expressionTargeted therapyEquivocal stainingBreast cancerCancer casesImmunohistochemical techniques
2013
Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).
Velcheti V, Schalper K, Carvajal D, Chen L, Sznol M, Gettinger S, Herbst R, Rimm D. Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 11075-11075. DOI: 10.1200/jco.2013.31.15_suppl.11075.Peer-Reviewed Original ResearchNon-small cell lung cancerTumor-infiltrating lymphocytesPresence of TILsGreek cohortBetter outcomesPDL1 expressionNSCLC casesProtein positivityAnti-PD-1 therapyDeath ligand 1 (PD-L1) expressionCell death ligand 1Quantitative immunofluorescenceComparable prognostic informationIndependent NSCLC cohortsPDL1 protein expressionLigand 1 expressionLonger overall survivalPDL1 mRNADeath ligand 1Cell lung cancerMRNA levelsAQUA methodNormal human placentaNSCLC cohortOverall survivalHigh SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas
Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, Deng Y, Gettinger S, Rimm DL. High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas. PLOS ONE 2013, 8: e61427. PMID: 23620753, PMCID: PMC3631238, DOI: 10.1371/journal.pone.0061427.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLonger survivalTissue microarrayMultivariate analysisIndependent lung cancer cohortsIndependent positive prognostic markerSOX2 levelsNon-small cell lung carcinomaQuantitative immunofluorescenceLung squamous cell carcinomaSecond independent validation cohortSOX2 expressionHigh SOX2 levelsLog rank pSOX2 overexpressionPositive prognostic markerRisk of deathClinico-pathological characteristicsClinico-pathological variablesCox univariate analysisIndependent validation cohortCell lung carcinomaLung cancer cohortNSCLC patientsOverall survival